EP Global Communications Inc fka EPGL

[H8ster]

On April 27th, shareholders will receive another update on the continued progress that EPGL is making. Since EPGL launched their business plan back in the spring of 2013, they have met and exceeded all Long term shareholder's expectations.

EP Global Communications, Inc., is a research and development company with focus on medical device design, ophthalmic medical device design, consumer electronic device design and device technologies in the IoT space. In 2014, all EPGL technologies and Intellectual property were selected and put under Development Agreement by CooperVision, Inc., a leading medical device manufacturer, for development and marketing. The EPGL team is now
securing Intellectual Properties and co-developing a family of advanced devices as a result. This Development Agreement was publicly disclosed on August 29, 2014. In addition, EPGL
has entered an initial Agreement with Intel Corporation. EPGL has also entered into Agreements with AT&T as of January 2015.

April 10th, 2015
EPGL Shareholder Update
EPGL to Release the Next Shareholder's Update on Monday April 27, 2015.

March 30, 2015
CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B
In a new material development to shareholders, EPGL has opened negotiations with CooperVision, Inc. at $1.1 billion for the exclusive Option to License their new ophthalmic technologies.
CooperVision, Inc. Seeks Intermediary as EP Global Communications, Inc., Opens Negotiations at $1.1B

March 17, 2015
EPGL Shareholder Update
EPGL's Next Major PR Update for Shareholders Will Be Monday, March 30, 2015.

March 16, 2015
CooperVision, Inc. Asks EP Global Communications, Inc. to Grant Option to License Immediately
"We understand why CooperVision, Inc. wants to acquire this Option to License sooner than later because the subject technologies will potentially enable $5 billion new dollars in the field of ophthalmic annually according to experts in the field," said Michael Hayes President of EPGL. "This is a very significant development and EPGL will look out for its interests in any negotiation and expects the Development Agreement to be adhered to."
CooperVision Option to License

March 16, 2015
EPGL and AT&T Developing Joint Intellectual Properties
Companies Sign Development Agreement Resulting in New Inventions in IoT Data Streaming Space
“The entire AT&T team was very impressive and they are driven to be on the forefront of IoT technologies of many varieties.” said Michael Hayes, President of EPGL. “We discussed some very interesting projects with them and their network capabilities are next to none. This is what makes them very interesting to be creating joint IP with at this time.”
EPGL and AT&T Developing Joint Intellectual Properties

March 3, 2015
EPGL Shareholder Update
We will have a major update PR release or release(s) on Monday March 16, 2015. This will include updates on new information about AT&T collaboration, CooperVision, and Intel. PR will be released pre-market hours, Monday March 16, 2015.

February 19, 2015
EPGL — Quarterly Report
Quarterly Report

February 18, 2015
EPGL — Supplemental Information
Supplemental Information

January 29, 2015
EPGL Major Beneficial Shareholders Agree to Commence Structure of Common Share Retirement
The two major beneficial shareholders being Mr. Michael Hayes, an individual shareholder and AJW Partners under the management by Pricewaterhouse Coopers (the Parties) have confirmed to the Company that they have agreed to a structure for on-going share retirement, independent of the Company.
Share Retirement

January 27, 2015
EPGL and AT&T Sign Development Agreement
EP Global Communications, Inc. and AT&T have signed a
Development Agreement which will serve as a starting point for
the two companies to explore potential projects together.
EPGL and AT&T Sign Development Agreement

December 5, 2014
Pricewaterhouse Coopers and EPGL Reach Agreement to Reduce Outstanding and Authorized Shares Beginning January 2015…………an agreement to mutually reduce their outstanding common share count by retiring a significant number of shares managed by PwC and matching shares held by Michael Hayes, Company President. The plan will be executed on January 30, 2015. This action involves no stock split of any kind.
Reduction of Outstanding & Authorized Shares

December 5, 2014
EPGL conducts Conference Call
Conference Call

November 17, 2014
EPGL - Financial Report
Quarterly Report

November 14, 2014
EPGL Shareholder Update
EPGL Talking with Hitachi as Adding to Arsenal for Achievement of Goals. Company Shareholders Update PR scheduled for December 5, 2014.

November 11, 2014
EPGL - Attorney Letter
Attorney Letter with Respect to Current Information

October 28, 2014
EPGL and Intel Corporation executed an initial Agreement. Additional Agreements are now pending...... EPGL management believes that a relationship with Intel will be advantageous to shareholders as the two companies have synergistic goals in various fields.
EPGL and Intel Corporation executed an initial Agreement

October 16, 2014
EPGL Shareholder Update
EPGL Has Now Entered an Initial Agreement with a NASDAQ Company, valued at more than $100 Billion market cap, to pursue Innovation in both Consumer Electronics and Wearable Technologies Synergies. Additional Agreements with This Particular Company Are Now Being Discussed at a High Level. EPGL Plans to Identify the New Company for Investors by October 28, 2014. A Press Release of Some Form Will Be Dispensed at that Time (Approx October 28th) Instead of October 21st as Previously Announced.

October 16, 2014
Management Discussion and Analysis
http://www.otcmarkets.com/financialReportViewer?symbol=EPGL&id=127312
Annual Report
http://www.otcmarkets.com/financialReportViewer?symbol=EPGL&id=127314

October 6th, 2014
EPGL - Annual Report
Annual Report

October 2nd, 2014
EPGL - Disclosure Statement
http://www.otcmarkets.com/financialReportViewer?symbol=EPGL&id=127169

September 26, 2014
EPGL Shareholder Update
On October 29, 2014, EPGL Will Finally File SEC FORM 10 and begin Again. On August 29th of this Year, EPGL disclosed it's first development agreement on OTC Markets. EPGL Is executing on It's plan to be a major leader in MEMS Technology, Wearable Technology and The Internet of Things.

September 18
EPGL Shareholder Update
EPGL moves next announcement date up to Tuesday October 21, 2014. Previous date announced was October 28, 2014.

September 12
EPGL Shareholder Update
EPGL Plans to Announce Agreement with Another Major Corporation on Tuesday, October 28, 2014.

September 7
EPGL Shareholder Update
In answer to some interested shareholders; No restricted shares of major EPGL beneficial shareholders have had restrictive legend removed to date and there are no plans to do so. The beneficial shareholders are focused on raising overall company and shareholder value. In addition, there will never be another reverse split. We believe that recent highs of share price are indicative of EPGL strength in the market based on real, tangible developments happening now, in real-time. We believe those recent highs can and will be surpassed. Team EPGL is quickly becoming recognized as an industry leader in the most innovative new MEMS technologies by other very large companies. and YES EPGL is already on multiple new filings of new intellectual property jointly, with other industry leading companies.

August 29
Exclusive Development Agreement Signed with CooperVision, Inc., a
Division of The Cooper Companies, Inc.
EP Global Communications, Inc. (EPGL) and CooperVision, Inc. (CooperVision) have signed an exclusive Development Agreement for advanced ophthalmic and medical technologies. CooperVision is a market leader in the manufacturing and marketing of contact
lenses.......
Development Deal with Cooper Companies

1. CooperVision has secured the exclusive right to co-develop EPGL advanced technologies of its choosing, with ownership of resulting intellectual property to be allocated in accordance with inventorships. EPGL has agreed to work exclusively with CooperVision in the ophthalmic and medical field to develop selected advanced technologies, granting CooperVision exclusive options to license or outright purchase EPGL’s rights to such
technologies. Under the Agreement, CooperVision will fund the co-development, prototyping, manufacturing and marketing of such technologies selected by CooperVision and negotiated project by project. This Development Agreement is on-going.

2. The companies are currently working on selection of technologies, prototyping, and securing intellectual property rights to the same.

3. This Development Agreement is a highly advantageous relationship for our shareholders because of the significant global resources that CooperVision brings to the table as a very
respected leader in the field of contact lens manufacturing. Under the terms of the Development Agreement, revenues from successful development of new products with CooperVision, will result from outright purchase of EPGL technologies and/or on-going
share of sales revenues as negotiated between the companies.

July 18, 2014
EPGL Shareholder Update
It can now be revealed that both Novartis and Google reached out to our development team members in recent weeks and months. This fact
should be a clue to the gravity and know-how of our team in both BioMEMS and manufacturing of smart contact lenses. We intend to set the industry's standard with our enabling technology. Who are we teamed up with? Who will ultimately include EPGL originated technology.

July 17, 2014
EPGL Shareholder Update
Google took glucose lens as far as they could. Now the "X" man is an ex-man. Enter Novartis to try to figure it out. But Novartis reached out to EPGL not long ago. So whose technology will dominate coming smart lens revolution? EPGL is leading giants and focused on new smart lens technologies which will enable mass marketing in both health and consumer electronics well into the future. Many companies and institutions stand to be enabled by our work. EPGL is working with the best in the business and more is to come by August 29, 2014. EPGL shareholders should be excited at the prospects.

June 30, 2014
EPGL - Disclosure Statement
Q1 2014 Disclosure Statement Update

June 19, 2014
EPGL Shareholder Update
EPGL is leading the advance MEMS technology design and product development for one of the largest companies in its field. The relationship has expanded under phase two and involves co -ownership of product technologies under development. All EPGL technologies are involved. The technology and products will be manufactured by the NYSE company branded under its name and distributed worldwide, by that Company and others affiliated. EPGL's role is that of research, design, development and ownership of the various technology applications. We are developing an "open source" platform with this company to enable many other organizations and entities to create new products with a new platform. EPGL shareholders should realize that this situation is very real and developing. We are getting very much closer to the time we can reveal all. This will happen no later than August 29, 2014.

EPGL is unlike any other OTC Pink Sheet company at this time. Shareholders are right to be excited about our future. By the way,EPGL and our partners could make an announcement sooner that August 29, 2014.

May 30, 2014
EPGL Shareholder Update
EPGL achieves Phase 2 of advanced technology development project. Another milestone and now closer to revelation for long shareholders.

May 18, 2014
EPGL - Balance Sheet
Q1 2014Balance Sheet, Income Statement & Cash Flow Statement

May 15, 2014
EPGL Shareholder Update
As EPGL has now transitioned to focus on a major MEMS technology development, the Company is transferring all MPD1 and MPTT future development and marketing to our distribution partners in Asia and the United States. As such, the MPD1 activity which has been stalled since 4th Quarter 2013, will begin to have new life in 2014 and our partners will pick up the ball and aggressively pursue sales of MPD1 starting 3rd Quarter 2014. As a result of this, EPGL will be enabled to focus 100% on major development projects which are important to the Company while reinvigorating the MPD1 and MPTT projects under our partners efforts. Q1 2014 financials, to be released within 72 hours, will reflect the transition of MPD1 and MPTT transition activity to our marketing partners. EPGL is essentially returning to "start-up" mode under the major development projects underway. Our future has never been brighter than it is right now in our opinion and we are working everyday to bring very significant value to our shareholders. We are also working to enlighten the investment community at large, to the incredible activities we are up to lately, leading giants, as soon as we possibly can. EPGL MEMS is leading!

EPGL is leading the giants with cutting edge technology. "We're at a new beginning and ground floor for EPGL with our recent reconfiguration of focus on the most significant opportunities. We think our most loyal shareholders will be amazed and excited about what they are part of." -Michael Hayes, President, EPGL.

April 15th, 2014
EPGL Shareholder Update
EPGL Announced Advanced Contact Lens Technology in August of 2013. Since then our technology and know how has caught the eyes of the world's leading companies in the field. Now, EPGL is on the forefront of innovating the technology and EPGL MEMS will be inside the world's most advanced contact lenses as we move into this new revolution of smart, wearable technology.

EPGL technologies are on the cutting edge and in demand. We believe current dedicated shareholders will be proven to be "visionary".

March 18, 2014
EPGL Shareholder Update
Meetings in Bay Area Recently, Went Well. EPGL is Positioned with Industry Leaders on Innovation of Wearables.

February 23, 2014
EPGL - Ammended Financials
Supplemental Information Ammended Q4 Financials

February 20, 2014
EPGL - Quarterly Report
Q4 2013 Quarterly Report

February 11, 2014
EPGL Developing Wearable Tech
EP Global Communications, Inc., (OTC Ticker EPGL) announces that as of fourth quarter 2013, EPGL has focused 100% on development of smart wearable technology. Because of recent developments and opportunities before the Company, EPGL has now established itself as an early player in the growing field. "Leading industry insiders believe wearable smart technology will be as large as the smart phone revolution. We agree with that," says David Markus Ph.D. while referencing Wired Magazine's January 2014 Cover Story. "Our unique technology and know-how, puts EPGL in demand. We've talked about this in our announcements since mid-2013."

"EPGL is very fortunate to be among a few serious players right now, who are pioneering this technology. These are visionary companies and people at the top of their field. We're
swimming with the big fish and nobody knows who we are just yet," said Michael Hayes, Company President. "But they will in due time."
EPGL Developing Wearable Tech

January 14, 2014
Pricewaterhouse Coopers, Ian Stokoe, pens letter confirming the deal EPGL made with a muti-billion dollar NYSE company.
......"In my view, this is a significant milestone and, as a major shareholder, I look forward to the future success of EPGL."
PWC Letter

December 16, 2013
EPGL Technology Selected by Major Corporation for Development
In a first for the company, one of EPGL's advanced technologies has been selected by a multi-billion dollar, NYSE publicly traded industry leader for development and integration into new products. "This is the biggest development for our company in its history," said David T. Markus PhD.”
EPGL Technology Selected by Major Corporation for Development

August 12, 2013
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices
New Smart Medical Devices Will Give Physicians Advanced Situational Awareness During Critical Procedures.
"EPGL is a company that is amassing advanced device technologies at a rapid pace and will make its mark with development of smarter medical devices." said David T. Markus PhD. "We have the advantage in advanced MEMS technology and this is the field that will revolutionize medicine in the next several years. EPGL shareholders are in a very special company at a special time."
EPGL Medical Invents Smart Epidural Needle, Nerve Ablation And Trigger Point Treatment Devices

August 7, 2013
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease
EPGL engineers have invented a new device for the purpose of treating serious eye diseases such as macular degeneration and retinitis pigmentosa. The technology emits low intensity pulse ultrasound into the eye for the purpose of regeneration of damaged cells and to possibly arrest the degeneration of existing healthy cells within the macula and the entire retina.
"The technology has proven to be very effective in recent research. We now have the ability to use MEMS to put the technology into the micro size environment for contact lenses.
EPGL Medical Invents New Cell Regeneration Technology For Eye Disease

June 18th, 2013
EPGL Medical Unveils New Devices and Intellectual Property Under EP Global Communications, Inc. Ownership
Advanced Device Prototypes on the Way Along with FDA 510k and PMA Applications.
New Devices and Intellectual Property
1. A new advanced ablation device for nerve pain treatment in the back.
2. A new advanced ablation device for nerve treatment of Facial Glabballar Frowning.
3. A new advanced device for elimination of facial wrinkles.
4. A new advanced Epidural device.
5. A new advanced power source for TopSpin medical devices.
6. A new and promising device for treatment of Retinitis Pigmentosa
7. A new and promising device for treatment of Macular Degeneration
8. A new and promising treatment for Hearing Loss
9. A new more accurate treatment for trigger points in the muscles (MPTT)
10. A new advanced device for treatment of prostate tumors.
11. A new advanced endoscopic device.
12. A new advanced device for delivery of micron sized drug payloads.
13. A new advanced device for delivery of micro mechanical devices into the body.
14. A new advanced device for biopsy.
15. A new advanced device for stem cell treatment delivery.
16. A new advanced contact lens device.